Holotransferrin enhances selective anticancer activity of artemisinin against human hepatocellular carcinoma cells

Abstract

Artemisinin, also termed qinghaosu, is extracted from the traditional Chinese medicine artemesia annua L. (the blue-green herb) in the early 1970s, which has been confirmed for effectively treating malaria. Additionally, emerging data prove that artemisinin exhibits anti-cancer effects against many types of cancers such as leukemia, melanoma, etc. Artemisinin becomes cytotoxic in the presence of ferrous iron. Since iron influx is high in cancer cells, artemisinin and its analogs selectively kill cancer cells with increased intracellular iron concentrations. This study is aimed to investigate the selective inhibitory effects of artemisinin on SMMC-7721 cells in vitro and determine the effect of holotransferrin, which increases the concentration of ferrous iron in cancer cells, combined with artemisinin on the anticancer activity. MTT assay was used for assessing the proliferation of SMMC-7721 cells treated with artemisinin. The induction of apoptosis and inhibition of colony formation in SMMC-7721 cells treated with artemisinin were determined by TdT-mediated dUTP nick end labeling (TUNEL) and colony formation assay, respectively. The results showed that artemisinin at various concentrations significantly inhibited growth, colony formation and cell viability of SMMC-7721 cells (P<0.05), likely due to induction of apoptosis of SMMC-7721 cells. Of interest, it was found that incubation of artemisinin combined with holotransferrin sensitized the growth inhibitory effect of artemisinin on SMMC-7721 cells (P<0.01). Our data suggest that treatment with artemisinin leads to inhibition of viability and proliferation, and apoptosis of SMMC-7721 cells. Furthermore, we observed that holotransferrin significantly enhanced the anti-cancer activity of artemisinin. This study may provide a potential therapeutic choice for liver cancer.

Keywords

human hepatocellular carcinoma SMMC-7721 cells / artemisinin / holotransferrin / cell growth / colony formation / apoptosis

References

[1] BadvieS. Hepatocellular carcinoma. Postgrad Med J, 2000, 76(891): 4-11

[2] HeSP, TanGY, LiG, et al.. Development of a sensitive monoclonal antibody-based enzyme-linked immunosorbent assay for the antimalaria active ingredient artemisinin in the Chinese herb Artemisia annua L. Anal Bioanal Chem, 2009, 393(4): 1297-1303

[3] SriramD, RaoVS, ChandrasekharaKV, et al.. Progress in the research of artemisinin and its analogues as antimalarials: an update. Nat Prod Res, 2004, 18(6): 503-527

[4] LiPC, LamE, RoosWP, et al.. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res, 2008, 68(11): 4347-4351

[5] DjimdeAA, FofanaB, SagaraI, et al.. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg, 2008, 78(3): 455-461

[6] MercerAE, Sarr SallahM. The pharmacokinetic evaluation of artemisinin drugs for the treatment of malaria in paediatric populations. Expert Opin Drug Metab Toxicol, 2011, 7(4): 427-439

[7] EfferthT, KainaB. Toxicity of the antimalarial artemisinin and its dervatives. Crit Rev Toxicol, 2010, 40(5): 405-421

[8] AdamI, ElhassanEM, OmerEM, et al.. Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women. Ann Trop Med Parasitol, 2009, 103(3): 205-210

[9] SmithuisF, KyawMK, PheO, et al.. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet, 2006, 367(9528): 2075-2085

[10] Bousejra-El GarahF, WongMH, AmewuRK, et al.. Comparison of the reactivity of antimalarial 1,2,4,5-tetraoxanes with 1,2,4-trioxolanes in the presence of ferrous iron salts, heme, and ferrous iron salts/phosphatidylcholine. J Med Chem, 2011, 54(19): 6443-6455

[11] AndersonKM, SeedT, OuD, et al.. Free radicals and reactive oxygen species in programmed cell death. Med Hypotheses, 1999, 52(5): 451-463

[12] DeugnierY, TurlinB. Iron and hepatocellular carcinoma. J Gastroenterol Hepatol, 2001, 16(5): 491-494

[13] KimKS, KimH, KimNG, et al.. Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. Hepatology, 2002, 35(6): 1459-1466

[14] LaiH, SasakiT, SinghNP, et al.. Effects of artemisinin-tagged holotransferrin on cancer cells. Life Sci, 2005, 76(11): 1267-1279

[15] TanWF, ShenF, LuoXJ, et al.. Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells. Phytomedicine, 2011, 18(2–3): 158-162

[16] KowdleyKV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology, 2004, 127(5Suppl1): S79-S86

[17] ChenJ, ChloupkovaM. Abnormal iron uptake and liver cancer. Cancer Biol Ther, 2009, 8(18): 1699-1708

[18] DengXR, YuHP, PanL, et al.. Artemisinin and holotransferrin induces apoptosis in hepatoma cells. Chin J Exp Surg (Chinese), 2008, 25(6): 802

[19] ReedJC. Mechanisms of apoptosis. Am J Pathol, 2000, 157(5): 1415-1430

[20] HanahanD, WeinbergRA. The hallmarks of cancer. Cell, 2000, 100(1): 57-70

[21] EvanGI, VousdenKH. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001, 411(6835): 342-348

[22] SinghNP, LaiHC. Artemisinin induces apoptosis in human cancer cells. Anticancer Res, 2004, 24(4): 2277-2280